

# Anti-LAG3 / CD223 Reference Antibody (fianlimab)

Recombinant Antibody Catalog # APR10361

# **Specification**

# Anti-LAG3 / CD223 Reference Antibody (fianlimab) - Product Information

Application FC, E, FTA
Primary Accession P18627
Reactivity Human
Clonality Monoclonal
Isotype IgG4SP
Calculated MW 146.46 KDa

# Anti-LAG3 / CD223 Reference Antibody (fianlimab) - Additional Information

Target/Specificity LAG3 / CD223

**Endotoxin** 

< 0.001EU/ µg,determined by LAL method.

**Conjugation** Unconjugated

**Expression system** 

CHO Cell

# **Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

# Anti-LAG3 / CD223 Reference Antibody (fianlimab) - Protein Information

Name LAG3 (HGNC:6476)

Synonyms FDC

## **Function**

Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:<a href="http://www.uniprot.org/citations/20421648" target="\_blank">20421648</a>, PubMed:<a href="http://www.uniprot.org/citations/7805750" target="\_blank">7805750</a>, PubMed:<a href="http://www.uniprot.org/citations/8647185" target="\_blank">8647185</a>). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and



Tel: 858.875.1900 Fax: 858.875.1999

CD4(+) T-cells (PubMed:<a href="http://www.uniprot.org/citations/20421648" target=" blank">20421648</a>, PubMed:<a href="http://www.uniprot.org/citations/7805750" target="blank">7805750</a>, PubMed:<a href="http://www.uniprot.org/citations/8647185" target="\_blank">8647185</a>). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed: <a href="http://www.uniprot.org/citations/8647185" target=" blank">8647185</a>).

### **Cellular Location**

[Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein

### **Tissue Location**


Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.

# Anti-LAG3 / CD223 Reference Antibody (fianlimab) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- Cell Culture


# Anti-LAG3 / CD223 Reference Antibody (fianlimab) - Images



Anti-LAG3 / CD223 Reference Antibody (fianlimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%







The purity of Anti-LAG3 / CD223 Reference Antibody (fianlimab) is more than 95% ,determined by SEC-HPLC.